Cellectis S.A.
Cellectis S.A. (CLLS): 4 pipeline candidates · 1 upcoming catalyst · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
N/A
D/E 3.28 · 0% dilution
Lead: Phase 2
4 candidates
1 upcoming, next in ~196d
N/A
A transparent, data-derived signal for Cellectis S.A.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$316.4M
Cash
$61.5M
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| CLLS52 | Phase 2 |
| UCART123v1.2 | Phase 2 |
| UCART20x22 | Phase 2 |
| UCART22 | Phase 2 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
29
Total value held
$3.6M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 341,523 | $1.1M |
| nomura asset management international inc. | 226,875 | $719K |
| eversource wealth advisors, llc | 5,092 | $525K |
| morgan stanley | 86,776 | $275K |
| susquehanna international group, llp | 65,942 | $209K |
| citadel advisors llc | 44,315 | $140K |
| marshall wace, llp | 41,112 | $130K |
| bnp paribas financial markets | 41,000 | $130K |
| ubs group ag | 29,774 | $94K |
| delaney dennis r | 24,000 | $76K |
Showing top 10 of 29 institutional holders of Cellectis S.A.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Cellectis S.A.'s pipeline?
Cellectis S.A. (CLLS) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Cellectis S.A.'s lead drug candidate?
Cellectis S.A.'s most advanced tracked candidate is CLLS52 (Phase 2) for B-cell Acute Lymphoblastic Leukemia; B-cell Non-Hodgkin Lymphoma (B-NHL).
What is Cellectis S.A.'s next catalyst?
Cellectis S.A.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: lasme-cel" — expected December 31, 2026.
What is Cellectis S.A.'s market capitalization?
Cellectis S.A.'s market capitalization is approximately $316.4M.
Who is the CEO of Cellectis S.A.?
Dr. Andre Choulika Ph.D. is the chief executive officer of Cellectis S.A. (CLLS).
Get the full picture on Cellectis S.A.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.